Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics, Genecast Biotechnology Ink Worldwide Research Services Agreement

NEW YORK – Interpace Diagnostics said today that its subsidiary Interpace BioPharma has partnered with Beijing, China-based Genecast Biotechnology to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies.  

As part of the collaboration, Parsippany, New Jersey-based Interpace will perform services worldwide except in China, where Genecast will provide services. 

"This collaboration is in line with our business strategy of driving sustainable, long-term growth and profitability by leveraging our unique capabilities," Michael McCartney, Interpace Biopharma chief commercial officer, said in a statement. 

Financial details of the agreement were not disclosed. 

"This partnership with Interpace will strengthen our capabilities to provide our customers with high-quality, streamlined one-stop testing services globally and is in line with our strategy of helping pharmaceutical and biotech companies to accelerate their biomarker-driven drug development and drive precision medicine forward," Genecast CEO and Cofounder Du Bo said in a statement.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.